Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2011 1
2014 1
2019 2
2020 1
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non-small-cell lung cancer in KEYNOTE-407.
Sugawara S, Tanaka K, Imamura F, Yamamoto N, Nishio M, Okishio K, Hirashima T, Tanaka H, Fukuhara T, Nakahara Y, Kurata T, Katakami N, Okada M, Horinouchi H, Udagawa H, Kasahara K, Satouchi M, Saka H, Tokito T, Hosomi Y, Aoe K, Kishi K, Ohashi K, Yokoyama T, Adachi N, Noguchi K, Schwarzenberger P, Kato T. Sugawara S, et al. Cancer Sci. 2023 Aug;114(8):3330-3341. doi: 10.1111/cas.15816. Epub 2023 May 15. Cancer Sci. 2023. PMID: 37183528 Free PMC article. Clinical Trial.
Matrix Metalloproteinase 9 Induced in Esophageal Squamous Cell Carcinoma Cells via Close Contact with Tumor-Associated Macrophages Contributes to Cancer Progression and Poor Prognosis.
Tsukamoto S, Koma YI, Kitamura Y, Tanigawa K, Azumi Y, Miyako S, Urakami S, Hosono M, Kodama T, Nishio M, Shigeoka M, Yokozaki H. Tsukamoto S, et al. Cancers (Basel). 2023 May 30;15(11):2987. doi: 10.3390/cancers15112987. Cancers (Basel). 2023. PMID: 37296952 Free PMC article.
Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study.
Seto T, Hayashi H, Satouchi M, Goto Y, Niho S, Nogami N, Hida T, Takahashi T, Sakakibara-Konishi J, Morise M, Nagasawa T, Suzuki M, Ohkura M, Fukuhara K, Thurm H, Peltz G, Nishio M. Seto T, et al. Cancer Sci. 2020 Oct;111(10):3726-3738. doi: 10.1111/cas.14576. Epub 2020 Sep 11. Cancer Sci. 2020. PMID: 32681682 Free PMC article.
KEYNOTE-025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small-cell lung cancer.
Nishio M, Takahashi T, Yoshioka H, Nakagawa K, Fukuhara T, Yamada K, Ichiki M, Tanaka H, Seto T, Sakai H, Kasahara K, Satouchi M, Han SR, Noguchi K, Shimamoto T, Kato T. Nishio M, et al. Cancer Sci. 2019 Mar;110(3):1012-1020. doi: 10.1111/cas.13932. Epub 2019 Feb 16. Cancer Sci. 2019. PMID: 30618179 Free PMC article. Clinical Trial.
Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509.
Satouchi M, Kotani Y, Shibata T, Ando M, Nakagawa K, Yamamoto N, Ichinose Y, Ohe Y, Nishio M, Hida T, Takeda K, Kimura T, Minato K, Yokoyama A, Atagi S, Fukuda H, Tamura T, Saijo N. Satouchi M, et al. J Clin Oncol. 2014 Apr 20;32(12):1262-8. doi: 10.1200/JCO.2013.53.5153. Epub 2014 Mar 17. J Clin Oncol. 2014. PMID: 24638015 Clinical Trial.
12 results